Original language | English (US) |
---|---|
Pages (from-to) | 423-428 |
Number of pages | 6 |
Journal | Journal of the American Academy of Child and Adolescent Psychiatry |
Volume | 46 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2007 |
Bibliographical note
Funding Information:Disclosure: None of the authors have conducted industry-funded studies of clozapine. Drs. Kumra, Kranzler, and Gerbino-Rosen have conducted studies of clozapine funded by the National Institute of Mental Health, but with study drug donated by Novartis. Dr. Kratochvil was previously a speaker for Novartis and has received grant support from, is a consultant to, and/or member of the speakers' bureaus of Eli Lilly, GlaxoSmithKline, Forest, Shire, Cephalon, Novartis, McNeil, Organon, AstraZeneca, and Pfizer. Dr. Findling has been a consultant to and conducted studies for Novartis, the manufacturer of Clozaril, and receives or has received research support from, acted as a consultant to, and/or served on the speakers' bureaus of Abbott, AstraZeneca, Bristol-Myers Squibb, Celltech-Medeva, Forest, GlaxoSmithKline, Johnson & Johnson, Lilly, New River, Novartis, Otsuka, Pfizer, Sanofi-Aventis, Shire, Solvay, and Wyeth. Dr. Frazier has received research support from, acted as a consultant to, and/or served on the speakers' bureaus of AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Research Institute, Johnson & Johnson Pharmaceutical Research and Development, Otsuka Pharmaceutical Inc., and Pfizer. The other authors have no financial relationships to disclose.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.